GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (NAS:MRSN) » Definitions » Pretax Margin %

Mersana Therapeutics (Mersana Therapeutics) Pretax Margin % : -182.64% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Mersana Therapeutics's Pre-Tax Income for the three months ended in Dec. 2023 was $-19.54 Mil. Mersana Therapeutics's Revenue for the three months ended in Dec. 2023 was $10.70 Mil. Therefore, Mersana Therapeutics's pretax margin for the quarter that ended in Dec. 2023 was -182.64%.

The historical rank and industry rank for Mersana Therapeutics's Pretax Margin % or its related term are showing as below:

MRSN' s Pretax Margin % Range Over the Past 10 Years
Min: -395488.37   Med: -465.8   Max: -54.43
Current: -465.8


MRSN's Pretax Margin % is ranked worse than
64.26% of 1027 companies
in the Biotechnology industry
Industry Median: -176.72 vs MRSN: -465.80

Mersana Therapeutics Pretax Margin % Historical Data

The historical data trend for Mersana Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Pretax Margin % Chart

Mersana Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only -66.97 -10,633.45 -395,488.37 -768.26 -465.80

Mersana Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -305.86 -719.85 -509.73 -541.13 -182.64

Competitive Comparison of Mersana Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Mersana Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mersana Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's Pretax Margin % falls into.



Mersana Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Mersana Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-171.67/36.855
=-465.80 %

Mersana Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-19.544/10.701
=-182.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mersana Therapeutics  (NAS:MRSN) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Mersana Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mersana Therapeutics (Mersana Therapeutics) Business Description

Traded in Other Exchanges
Address
840 Memorial Drive, Cambridge, MA, USA, 02139
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Executives
Anna Protopapas director, officer: President and CEO MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Mohan Bala officer: SVP, Chief Development Officer C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Tushar Misra officer: Chief Manufacturing Officer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Deschuytner officer: Sr. VP, Finance & Product stgy 840 MEMORIAL DRIVE, CAMBRIDGE MA 01776
Ashish Mandelia officer: VP, Controller 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Timothy B Lowinger officer: Chief Scientific Officer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alejandra Carvajal officer: Chief Legal Officer C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Arvin Yang officer: Chief Medical Officer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Michael J. Kaufman officer: Sr VP Chmistry, Man & Control 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Eva M. Jack officer: CBO, Treasurer & Secretary 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Scott D Sandell 10 percent owner